The 13th China Pharmaceutic Preparation Conference 2019 hosted by the Chinese Pharmaceutical Association was grandly held in Yantai, Shandong on October 11-13, at which the list of the most innovative preparation varieties in China for the year of 2019 was released. China's first independently developed long-acting hypoglycemic drug, polyethylene glycol loxenatide injection, which has attracted much attention from diabetes doctors and patients, was on this list.
This list was determined after evaluation and review by experts randomly selected by the Pharmaceutical Preparation Expert Committee of the Chinese Pharmaceutical Association, and the evaluation basis includes the market position advantage of the drug in the treatment field, the competitive advantage in the future market, the growth and stability of the enterprise itself, and the sustainability of the enterprise's management strategy deployment.
The trade name of polyethylene glycol loxenatide injection is Fulaimei. It is the second Class 1 innovative drug independently developed by Hansoh Pharma, the first long-acting GLP-1 receptor agonist independently innovated in China, and the first PEGylate long-acting GLP-1 receptor agonist in the world, used to improve blood glucose control in adult patients with type 2 diabetes.
Since its launch in June this year, Fulaimei has attracted widespread attention due to its significant improvement in easy medication and patient compliance. “It will provide a new strategy for diabetes treatment”, “Administered once per week, Fulaimei will bring good news to diabetic patients”, well-known endocrinologists in China were quoted saying so to express their great expectations on Fulaimei at the launch meeting in China.
According to Professor Shan Zhongyan, Vice Chairman of the Chinese Society of Endocrinology of the Chinese Medical Association, the research and development of Fulaimei adopts the “patient needs centered” approach; it can significantly reduce the incidence of adverse reactions while controlling blood glucose, provide multiple benefits such as weight loss, and bring fewer injections, easier operation and better compliance.
Academician Ning Guang, head of the Chinese Association of Endocrinology and Metabolism Physicians of the Chinese Medical Doctor Association, noted that China's first long-acting GLP-1 preparation with independent intellectual property rights, Fulaimei, is a major innovation in diabetes treatment drugs in China, providing clinicians with new treatment options.
Fulaimei definitely deserves the recognition as one of the “Most Innovative Preparation Varieties in China 2019”, and is expected to bring better medication experience and a healthier life to more patients.
